NOXXON's Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference
NOXXON Pharma AG announced that Prof. Hermann Haller, Director of the Department of Nephrology and Hypertension at Hanno…
NOXXON Pharma AG announced that Prof. Hermann Haller, Director of the Department of Nephrology and Hypertension at Hanno…
NOXXON Pharma AG gab bekannt, dass Proof-of-Concept-Daten einer Phase-IIa-Studie mit Emapticap Pegol (NOX-E36) in diabet…
NOXXON Pharma AG announced that Phase IIa proof-of-concept data from the emapticap pegol (NOX-E36) trial in diabetic nep…
NOXXON Pharma gab heute den erfolgreichen Abschluss der Patientenrekrutierung für die klinische Studie der Phase IIa mi…
NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial f…
NOXXON Pharma AG gab heute die Behandlung des ersten Patienten in einer Phase IIa-Studie mit dem Anti-CCL2/MCP-1 (C-C Ch…
NOXXON Pharma today announced the treatment of the first patient in a Phase IIa clinical trial of its anti-CCL2/MCP-1 (C…
NOXXON Pharma AG announced today that it has permission to commence a multiple ascending dose study of its Monocyte Chem…
Die NOXXON Pharma AG gab heute bekannt, dass sie die Genehmigung für den Beginn einer Studie mit steigenden Mehrfachdose…
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprieta…